An Open-Label, Dose-Finding Study of Vedolizumab IV Plus Standard of Care for Graft-Versus-Host Disease (GvHD) Prophylaxis in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 16 Mar 2018
At a glance
- Drugs Vedolizumab (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Takeda
- 12 Mar 2018 Planned End Date changed from 31 Dec 2018 to 22 Jun 2018.
- 12 Mar 2018 Planned primary completion date changed from 31 Mar 2018 to 22 Jun 2018.
- 12 Mar 2018 Status changed from recruiting to active, no longer recruiting.